Search research articles
Contact Us
Filters
Showing results (11-20 of 134) with videos related to
Page
of 14
Sort By:
Recenti Progressi in Medicina
|
April 12, 2017
Elderly patients with advanced pancreatic cancer: the generalizability of the results of clinical trials to daily clinical practice
Jacopo Giuliani, Andrea Bonetti
Expert Review of Pharmacoeconomics & Outcomes Research
|
August 6, 2019
Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatment
Jacopo Giuliani, Andrea Bonetti
Cancer Biotherapy & Radiopharmaceuticals
|
June 29, 2012
Immunotherapy and targeted therapies in metastatic renal cell carcinoma: is there a preferred sequence?
Jacopo Giuliani, Fabrizio Drudi
Journal of Gastrointestinal Cancer
|
November 27, 2012
Multidisciplinary approach as the key factor in the management of liver metastases from colorectal cancer
Jacopo Giuliani, Marina Marzola
European Journal of Cancer (Oxford, England : 1990)
|
October 16, 2018
Which grade is of clinical benefit in the randomised controlled trials? The example of 54th American Society of Clinical Oncology annual meeting, 2018
Jacopo Giuliani, Andrea Bonetti
Clinical Colorectal Cancer
|
March 19, 2018
Regorafenib or Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer? A Perspective on the Basis of Pharmacological Costs
Jacopo Giuliani, Andrea Bonetti
Journal of Medical Virology
|
August 12, 2020
Cancer prevales on COVID-19: To maintain high quality standard concerning diagnosis and oncological care even during a pandemic
Jacopo Giuliani, Andrea Bonetti
International Journal of Colorectal Disease
|
September 15, 2020
To perform genotyping of dihydropyrimidine dehydrogenase (DPD) before starting treatment with 5-fluorouracil or related medicines: really feasible?
Jacopo Giuliani, Andrea Bonetti
The Breast Journal
|
September 13, 2020
The cost-effectiveness of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer is supported by clinical evidence
Jacopo Giuliani, Andrea Bonetti
European Urology
|
November 4, 2017
Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041: Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment?
Jacopo Giuliani, Andrea Bonetti
Page
of 14
Search research articles
Search
Showing results (11-20 of 134) with videos related to
Sort By:
Page
of 14
Recenti Progressi in Medicina
|
April 12, 2017
Elderly patients with advanced pancreatic cancer: the generalizability of the results of clinical trials to daily clinical practice
Jacopo Giuliani, Andrea Bonetti
Expert Review of Pharmacoeconomics & Outcomes Research
|
August 6, 2019
Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatment
Jacopo Giuliani, Andrea Bonetti
Cancer Biotherapy & Radiopharmaceuticals
|
June 29, 2012
Immunotherapy and targeted therapies in metastatic renal cell carcinoma: is there a preferred sequence?
Jacopo Giuliani, Fabrizio Drudi
Journal of Gastrointestinal Cancer
|
November 27, 2012
Multidisciplinary approach as the key factor in the management of liver metastases from colorectal cancer
Jacopo Giuliani, Marina Marzola
European Journal of Cancer (Oxford, England : 1990)
|
October 16, 2018
Which grade is of clinical benefit in the randomised controlled trials? The example of 54th American Society of Clinical Oncology annual meeting, 2018
Jacopo Giuliani, Andrea Bonetti
Clinical Colorectal Cancer
|
March 19, 2018
Regorafenib or Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer? A Perspective on the Basis of Pharmacological Costs
Jacopo Giuliani, Andrea Bonetti
Journal of Medical Virology
|
August 12, 2020
Cancer prevales on COVID-19: To maintain high quality standard concerning diagnosis and oncological care even during a pandemic
Jacopo Giuliani, Andrea Bonetti
International Journal of Colorectal Disease
|
September 15, 2020
To perform genotyping of dihydropyrimidine dehydrogenase (DPD) before starting treatment with 5-fluorouracil or related medicines: really feasible?
Jacopo Giuliani, Andrea Bonetti
The Breast Journal
|
September 13, 2020
The cost-effectiveness of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer is supported by clinical evidence
Jacopo Giuliani, Andrea Bonetti
European Urology
|
November 4, 2017
Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041: Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment?
Jacopo Giuliani, Andrea Bonetti
Page
of 14